A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
Background Escalating healthcare costs are necessitating the practice of value-based
oncology. It is crucial to critically evaluate the economic impact of influential but expensive …
oncology. It is crucial to critically evaluate the economic impact of influential but expensive …
[HTML][HTML] Financial toxicity and implications for cancer care in the era of molecular and immune therapies
G Tran, SY Zafar - Annals of translational medicine, 2018 - ncbi.nlm.nih.gov
Molecular and immune therapies have revolutionized cancer treatment and improved
patient outcomes and survival. However, the pricing of these drugs has become an issue as …
patient outcomes and survival. However, the pricing of these drugs has become an issue as …
A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity
Checkpoint blockade therapy has provided noteworthy benefits in multiple cancers in recent
years; however, its clinical benefits remain confined to 10–40% of patients with extremely …
years; however, its clinical benefits remain confined to 10–40% of patients with extremely …
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
G Thanarajasingam, LM Minasian, F Baron… - The Lancet …, 2018 - thelancet.com
Tremendous progress in treatment and outcomes has been achieved across the whole
range of haematological malignancies in the past two decades. Although cure rates for …
range of haematological malignancies in the past two decades. Although cure rates for …
Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma …
Purpose Ipilimumab induces durable remission in about 15–20% of patients with metastatic
melanoma. However, reliable predictors of response to ipilimumab are currently lacking …
melanoma. However, reliable predictors of response to ipilimumab are currently lacking …
Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
D Ding, H Hu, S Li, Y Zhu, Y Shi, M Liao, J Liu… - Journal of the National …, 2021 - jnccn.org
Background: In the CASPIAN trial, durvalumab 1 chemotherapy demonstrated significant
improvements in overall survival compared with chemotherapy alone in patients with …
improvements in overall survival compared with chemotherapy alone in patients with …
Nivolumab vs pembrolizumab for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a network meta …
R Pei, Y Shi, S Lv, T Dai, F Zhang, S Liu… - JAMA network …, 2021 - jamanetwork.com
Importance Nivolumab and pembrolizumab are approved for treating platinum-refractory
recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Physicians …
recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Physicians …
Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non–small cell lung cancer
PT Courtney, AT Yip, DR Cherry, MA Salans… - JAMA network …, 2021 - jamanetwork.com
Importance Treatment with nivolumab-ipilimumab combination therapy was found to
improve overall survival compared with chemotherapy among patients with advanced non …
improve overall survival compared with chemotherapy among patients with advanced non …
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
E Mulder, K De Joode, S Litière, AJ Ten Tije… - BMC cancer, 2021 - Springer
Background The introduction of programmed cell death protein 1 (PD-1) blockers (ie
nivolumab and pembrolizumab) has significantly improved the prognosis of patients with …
nivolumab and pembrolizumab) has significantly improved the prognosis of patients with …
Cost-effectiveness of pembrolizumab as a second-line therapy for hepatocellular carcinoma
Importance Immune checkpoint inhibitors have been approved for use as a second-line
therapy for hepatocellular carcinoma (HCC) in patients who previously received sorafenib …
therapy for hepatocellular carcinoma (HCC) in patients who previously received sorafenib …